Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 71, Issue 1, Pages 161-169Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2014.02.035
Keywords
adverse event management; dermatologic; immune-related; ipilimumab; melanoma; pruritus; rash; vitiligo
Categories
Funding
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Boehringer Ingelheim
- Celgene
- Eisai
- GSK
- IGEA
- Lilly
- MelaSciences
- Merck Serono
- MSD/Merck
- Novartis
- Oncosec
- Roche Pharma
Ask authors/readers for more resources
Ipilimumab is a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumor T-cell responses. Phase III studies have demonstrated survival benefit in both previously treated and treatment-naive patients with metastatic melanoma. In clinical trials, adverse events (AEs) related to treatment with ipilimumab were mostly grade 1/2 (as per Common Terminology Criteria for AEs, Version 4.02), and mostly reversible with appropriate management. Distinct immune-related AEs that may reflect the mechanism of action of ipilimumab have been identified, and occur commonly in the skin, typically presenting as a maculopapular rash, which can be accompanied by pruritus, pruritus with no skin lesions, alopecia, and vitiligo. Histologic analyses have revealed epidermal spongiosis, and perivascular CD4(+) T-cell infiltrates with some eosinophils in areas of rash. Timely implementation of toxicity-specific treatment guidelines that emphasize vigilance and early intervention allows mitigation of dermatologic AEs. Adherence to guidelines is necessary to maintain quality of life, ensure consistent dosing, and obtain the best possible clinical outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available